IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

Natural Naive CD4 + CD25 + CD127 low Regulatory T Cell (Treg) Development and Function Are Disturbed in Multiple Sclerosis Patients: Recovery of Memory Treg Homeostasis during Disease Progression

(2014) Koen Venken et al.   JOURNAL OF IMMUNOLOGY

Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression

(2014) L. Strauss et al.   JOURNAL OF IMMUNOLOGY

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells

(2012) J. Faget et al.   CANCER RESEARCH

Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells

(2012) C. Conrad et al.   CANCER RESEARCH

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Helios Expression Is a Marker of T Cell Activation and Proliferation

(2011) Tatiana Akimova et al.   PLoS One

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

CD73: A Novel Target for Cancer Immunotherapy

(2010) B. Zhang   CANCER RESEARCH

Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells

(2010) N. Martin-Orozco et al.   CANCER RESEARCH

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

(2010) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells

(2010) Marc Vocanson et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+ T Regulatory Cells Correlates with Progressive Disease

(2010) J. Schulze zur Wiesch et al.   JOURNAL OF VIROLOGY

Proximal human FOXP3 promoter transactivated by NF-κB and negatively controlled by feedback loop and SP3

(2010) Paul Eckerstorfer et al.   MOLECULAR IMMUNOLOGY

FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease

(2009) I. Kryczek et al.   CANCER RESEARCH

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis

(2009) C Coquerelle et al.   GUT

Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?

(2009) Maria A. Curotto de Lafaille et al.   IMMUNITY

Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor

(2009) Makoto Miyara et al.   IMMUNITY

PD-1 tempers Tregs in chronic HCV infection

(2009) Henry Radziewicz et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV

(2009) Debora Franceschini et al.   JOURNAL OF CLINICAL INVESTIGATION

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

(2009) Marianna Sabatino et al.   JOURNAL OF CLINICAL ONCOLOGY

Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression

(2009) Magis Mandapathil et al.   JOURNAL OF IMMUNOLOGICAL METHODS

CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis

(2009) J. M. Fletcher et al.   JOURNAL OF IMMUNOLOGY

Regulatory T cells and treatment of cancer

(2008) Tyler J Curiel   CURRENT OPINION IN IMMUNOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

IL-2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells

(2008) Susan Brandenburg et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery

(2008) Tomoki Ito et al.   IMMUNITY

CD56brightnatural killer (NK) cells: an important NK cell subset

(2008) Aurélie Poli et al.   IMMUNOLOGY

Next Generation of Immunotherapy for Melanoma

(2008) John M. Kirkwood et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA